Ozge Oztan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2952569/publications.pdf

Version: 2024-02-01

18	707	623734	888059
papers	citations	14 h-index	17 g-index

18	18	18	1069
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Autism-associated biomarkers: testâ€“retest reliability and relationship to quantitative social trait variation in rhesus monkeys. Molecular Autism, 2021, 12, 50.	4.9	10
2	Inter-individual differences in immune profiles of outbred rats screened for an emotional reactivity phenotype. Journal of Neuroimmunology, 2020, 347, 577349.	2.3	0
3	Neonatal CSF vasopressin concentration predicts later medical record diagnoses of autism spectrum disorder. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10609-10613.	7.1	39
4	Blood oxytocin concentration positively predicts contagious yawning behavior in children with autism spectrum disorder. Autism Research, 2019, 12, 1156-1161.	3.8	17
5	A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Science Translational Medicine, 2019, 11, .	12.4	106
6	Biomarker discovery for disease status and symptom severity in children with autism. Psychoneuroendocrinology, 2018, 89, 39-45.	2.7	28
7	Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates. Science Translational Medicine, 2018, 10, .	12.4	50
8	Cerebrospinal fluid vasopressin and symptom severity in children with autism. Annals of Neurology, 2018, 84, 611-615.	5.3	40
9	Preference for novel faces in male infant monkeys predicts cerebrospinal fluid oxytocin concentrations later in life. Scientific Reports, 2017, 7, 12935.	3.3	15
10	Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8119-8124.	7.1	252
11	Hippocampal Y2 receptor-mediated mossy fiber plasticity is implicated in nicotine abstinence-related social anxiety-like behavior in an outbred rat model of the novelty-seeking phenotype. Pharmacology Biochemistry and Behavior, 2014, 125, 48-54.	2.9	6
12	Long-term effects of juvenile nicotine exposure on abstinence-related social anxiety-like behavior and amygdalar cannabinoid receptor 1 (CB1R) mRNA expression in the novelty-seeking phenotype. Behavioural Brain Research, 2012, 228, 236-239.	2.2	12
13	Nicotine-induced anxiety-like behavior in a rat model of the novelty-seeking phenotype is associated with long-lasting neuropeptidergic and neuroplastic adaptations in the amygdala: Effects of the cannabinoid receptor 1 antagonist AM251. Neuropharmacology, 2012, 63, 1335-1345.	4.1	20
14	Effects of a selective Y2R antagonist, JNJ-31020028, on nicotine abstinence-related social anxiety-like behavior, neuropeptide Y and corticotropin releasing factor mRNA levels in the novelty-seeking phenotype. Behavioural Brain Research, 2011, 222, 332-341.	2.2	24
15	Vulnerability to nicotine abstinence-related social anxiety-like behavior: Molecular correlates in neuropeptide Y, Y2 receptor and corticotropin releasing factor. Neuroscience Letters, 2011, 490, 220-225.	2.1	27
16	Stressful environmental and social stimulation in adolescence causes antidepressant-like effects associated with epigenetic induction of the hippocampal BDNF and mossy fibre sprouting in the novelty-seeking phenotype. Neuroscience Letters, 2011, 501, 107-111.	2.1	15
17	Chronic variable physical stress during the peripubertal-juvenile period causes differential depressive and anxiogenic effects in the novelty-seeking phenotype: functional implications for hippocampal and amygdalar brain-derived neurotrophic factor and the mossy fibre plasticity. Neuroscience, 2011, 192, 334-344.	2.3	27
18	Effects of a cannabinoid receptor (CB) 1 antagonist AM251 on behavioral sensitization to nicotine in a rat model of novelty-seeking behavior: correlation with hippocampal 5HT. Psychopharmacology, 2009, 203, 23-32.	3.1	19